Zhonghua Gan Zang Bing Za Zhi. 2021 Oct 20;29(10):942-947. doi: 10.3760/cma.j.cn501113-20210927-00485.
The disease burden of hepatocellular carcinoma in our country is serious, and the prognosis is not ideal. Therefore, early screening of high-risk groups of hepatocellular carcinoma through simple methods is the key to achieving early diagnosis and treatment and improving survival. At present, alpha fetoprotein (AFP) and other hematological tests are still the main methods in the early screening of hepatocellular carcinoma, but their sensitivity and specificity are limited, and the risk of missed diagnosis is high. In recent years, with the continuous development of science and technology, the improvement of traditional detection methods and the emergence of new markers such as methylated DNA and miRNA have brought hope for further improving the sensitivity and specificity of early hepatocellular carcinoma screening. This consensus summarizes the research progress of traditional and new hematological examination methods, and puts forward the expert guidance on the role of hematological markers in the early screening of hepatocellular carcinoma; with aim to provide a basis for improving the prevention and control level in China.
我国肝细胞癌的疾病负担严重，预后不理想。因此，通过简单方法对肝细胞癌高危人群进行早期筛查是实现早期诊断和治疗以及提高生存率的关键。目前，甲胎蛋白（AFP）等血液学检查仍是肝细胞癌早期筛查的主要方法，但其敏感性和特异性有限，漏诊风险高。近年来，随着科技的不断发展，传统检测方法的改进以及甲基化DNA和miRNA等新标志物的出现，为进一步提高肝细胞癌早期筛查的敏感性和特异性带来了希望。本共识总结了传统和新型血液学检查方法的研究进展，提出了血液学标志物在肝细胞癌早期筛查中作用的专家指导意见；旨在为提高我国的防控水平提供依据。
